menu
    • menu
    [{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Remetinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"TetraLogic","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Remetinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"TetraLogic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TetraLogic \/ Medivir","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic \/ Medivir"}]

    Find Clinical Drug Pipeline Developments & Deals for Remetinostat

    Menu

    Remetinostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TetraLogic

                            Country arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            TetraLogic

                            Country arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Medivir Strengthens the Business Development Potential of Remetinostat Through Renegotiated Multi-Party Agreem...

                            Details : The companies have restructured and streamlined the financial obligations for remetinostat, a topical histone deacetylase inhibitor, for the treatment of cutaneous T-cell lymphoma and other types of skin cancers.

                            Brand Name : SHP-141

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 16, 2021

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medivir

                            Sweden arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous...

                            Details : The primary objective of the study was to assess the effects of topical remetinostat on biopsy-proven SCC and SCC in situ tumors.

                            Brand Name : SHP-141

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 20, 2021

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth